Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst, Jens Juul

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. [electronic resource] - Expert opinion on emerging drugs May 2004 - 155-66 p. digital

Publication Type: Journal Article; Review

1744-7623

10.1517/eoed.9.1.155.32952 doi


Adenosine Deaminase--physiology
Adenosine Deaminase Inhibitors
Afferent Pathways--physiology
Animals
Appetite--drug effects
Diabetes Mellitus, Experimental--drug therapy
Diabetes Mellitus, Type 2--drug therapy
Dipeptidyl Peptidase 4--physiology
Drug Therapy, Combination
Exenatide
Glucagon--agonists
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Glycoproteins--antagonists & inhibitors
Humans
Hypoglycemic Agents--administration & dosage
Hypothalamus--drug effects
Insulin--biosynthesis
Insulin Secretion
Intestinal Mucosa--innervation
Islets of Langerhans--drug effects
Liraglutide
Lizards
Maleimides--therapeutic use
Mice
Mice, Knockout
Mice, Obese
Peptide Fragments--agonists
Peptides--pharmacology
Proglucagon
Protein Precursors--agonists
Rats
Rats, Zucker
Receptors, Glucagon--agonists
Venoms--pharmacology